Portnoy Law Firm Announces Class Action on Behalf of Unicycive Therapeutics, Inc. Investors
Unicycive Therapeutics, Inc. (UNCY)
Company Research
Source: GlobeNewswire
LOS ANGELES, Oct. 13, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Unicycive Therapeutics, Inc., (“Unicycive” or the "Company") (NASDAQ: UNCY) investors off a class action on behalf of investors that bought securities between March 29, 2024 and June 27, 2025, inclusive (the “Class Period”). Unicycive investors have until October 14, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or join the case via https://portnoylaw.com/unicycive-therapeutics-inc. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses. On June 30, 2025, Unicycive release issued a press release “announc[ing] that the U.S. Food and Drug Administration (FDA) has issued a CRL [Complete Response Letter] for its New Drug Application (NDA) for OLC to treat hyperphosphatemia in patients w
Show less
Read more
Impact Snapshot
Event Time:
UNCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UNCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UNCY alerts
High impacting Unicycive Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
UNCY
News
- Unicycive Therapeutics (NASDAQ:UNCY) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Unicycive Therapeutics to Participate in Upcoming Investor Events in December [Yahoo! Finance]Yahoo! Finance
- Unicycive Therapeutics to Participate in Upcoming Investor Events in DecemberGlobeNewswire
- Retail investors who hold 48% of Unicycive Therapeutics, Inc. (NASDAQ:UNCY) gained 23%, institutions profited as well [Yahoo! Finance]Yahoo! Finance
- Unicycive Therapeutics GAAP EPS of -$0.46 beats by $0.07 [Seeking Alpha]Seeking Alpha
UNCY
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form 8-K
- 11/14/25 - Form 424B5
- UNCY's page on the SEC website